In a 36‑year‑old man with intermittent constipation for 6–9 months, daily epigastric dull aching pain and bloating that improved after H. pylori eradication therapy (omeprazole, tetracycline, metronidazole, bismuth) but recurred one month ago, and a colonoscopy that was essentially normal except for a transverse colon polyp, what is the appropriate management of his recurrent dyspepsia and constipation?

Management of Recurrent Dyspepsia After H. pylori Eradication

This patient requires retesting for H. pylori recurrence/reinfection and empiric PPI therapy for his ulcer-like dyspepsia symptoms while awaiting test results.

Immediate Diagnostic Approach

The first priority is to confirm whether H. pylori has recurred. Perform a urea breath test (UBT) or monoclonal stool antigen test at least 4 weeks after completing PPI therapy 1. Serology has no role here. The patient's negative test was performed appropriately, but symptom recurrence one month ago raises concern for:

• Recrudescence (same strain persisting despite negative test)
• True reinfection (new infection, though less likely in this timeframe)
• Functional dyspepsia unmasked after successful eradication

Critical Testing Considerations:

• Ensure the patient is off PPIs for at least 2 weeks before testing (ideally 4 weeks) to avoid false negatives
• The patient's symptoms (epigastric pain worse with fasting, improved with eating) are classic for ulcer-like dyspepsia and suggest acid-related pathology

Management Algorithm

If H. pylori Test is POSITIVE (Recurrence/Reinfection):

Second-line therapy is required since the patient already received bismuth quadruple therapy (omeprazole, tetracycline, metronidazole, bismuth). Based on 2021 AGA guidelines for refractory H. pylori 2:

Preferred regimen: Levofloxacin triple therapy for 14 days:

• High-dose PPI (omeprazole 40 mg or equivalent) twice daily
• Amoxicillin 1000 mg three times daily (or 500 mg four times daily)
• Levofloxacin 500 mg once daily

Alternative regimen: Rifabutin triple therapy for 14 days:

• High-dose PPI twice daily
• Amoxicillin 1000 mg twice daily
• Rifabutin 150 mg twice daily

Key considerations:

• Review prior antibiotic exposures—if he has received fluoroquinolones for any reason, avoid levofloxacin-based therapy 2
• Resistance to amoxicillin, tetracycline, and rifabutin remains rare 2
• After two failed therapies, susceptibility testing should be considered 2
• Ensure adequate acid suppression with high-dose PPI or consider vonoprazan if available 3

If H. pylori Test is NEGATIVE:

This represents functional dyspepsia (ulcer-like subtype) and requires symptomatic management.

First-line therapy: Full-dose PPI therapy 4:

• Omeprazole 20 mg once daily before meals for 4-8 weeks
• His symptom pattern (epigastric pain relieved by eating, worse when fasting) strongly predicts PPI response 4

Treatment approach:

1. Initial 4-week trial of PPI
2. If symptoms resolve, attempt withdrawal and use on-demand therapy for recurrences 4
3. If symptoms persist after 4 weeks, continue for additional 4 weeks
4. If no response after 8 weeks total, consider upper endoscopy to exclude H. pylori-negative peptic ulcer 4

Management of Constipation

The constipation component requires separate attention:

• Dietary modifications: Increase fiber intake, adequate hydration
• Consider osmotic laxatives if dietary measures insufficient (polyethylene glycol is first-line)
• Avoid chronic stimulant laxative use
• The colonoscopy was reassuring (single tubular adenoma, otherwise normal)

Common Pitfalls to Avoid

1. Do not assume eradication was successful just because one test was negative—recurrence can occur 1
2. Do not use clarithromycin-based regimens for second-line therapy after bismuth quadruple failure 2
3. Do not undertreat with inadequate PPI dosing—use high-dose twice-daily dosing for retreatment 2
4. Do not test for H. pylori while on PPI—this causes false negatives 1
5. Do not continue empiric antibiotics without confirming persistent infection—functional dyspepsia is common after successful eradication 4

Follow-Up Strategy

• Confirm eradication 4-8 weeks after completing second-line therapy with UBT or stool antigen test 1
• If symptoms persist despite confirmed eradication, manage as functional dyspepsia with PPI therapy 4
• Consider upper endoscopy if alarm features develop or symptoms fail to respond to empiric therapy 4
• The patient's young age (36 years) and lack of alarm symptoms make serious pathology unlikely, but his colonoscopy finding of a polyp warrants appropriate surveillance per guidelines